Related Experiment Videos
Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas
1Department of Molecular Genetics, Ruder Bosković Institute, Zagreb, Croatia. osmak@rudjer.irb.hr
Neoplasma
|April 13, 2002
Summary
This study found higher levels of urokinase plasminogen activator (uPA), PAI-1, and PAI-2 in endometrial cancer tissues. PAI-2 levels correlated with advanced cancer stages and invasion, suggesting its role in disease progression.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Proteases play a role in cancer development and spread.
- Understanding protease levels can aid in early cancer detection and patient prognosis.
Purpose of the Study:
- To measure urokinase plasminogen activator (uPA), PAI-1, and PAI-2 levels in normal and malignant endometrial tissues.
- To correlate these protein levels with clinical and histopathological prognostic factors in endometrial carcinoma.
Main Methods:
- ELISA assay used to quantify uPA, PAI-1, and PAI-2 in tissue cytosol.
- Matched tissue samples from 27 endometrial carcinoma patients were analyzed.
Main Results:
- Significantly elevated levels of uPA, PAI-1, and PAI-2 were observed in malignant endometrial tissues compared to normal tissues.
- uPA and PAI-1 levels did not correlate with clinical staging or histopathological grading.
- Increased PAI-2 levels were found in tumors with advanced stages (II and III), deep myometrial invasion, and lymphovascular invasion.
Conclusions:
- Components of the plasminogen activation system are upregulated in endometrial cancer.
- PAI-2 may be a significant factor in determining the invasive potential of endometrial carcinomas.